Galectin Therapeutics (NASDAQ:GALT) Downgraded to Sell Rating by Wall Street Zen

Posted by on May 17th, 2026

Wall Street Zen downgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a hold rating to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings lowered shares of Galectin Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 4th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $11.00.

Get Our Latest Research Report on GALT

Galectin Therapeutics Trading Down 7.7%

Shares of GALT stock opened at $2.17 on Friday. Galectin Therapeutics has a 1 year low of $1.21 and a 1 year high of $7.13. The firm’s fifty day moving average price is $2.57 and its two-hundred day moving average price is $3.69. The firm has a market capitalization of $142.85 million, a P/E ratio of -5.29 and a beta of 0.45.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). As a group, equities research analysts forecast that Galectin Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP bought a new position in shares of Galectin Therapeutics in the 3rd quarter valued at about $70,000. Bank of America Corp DE grew its position in shares of Galectin Therapeutics by 101.4% in the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after acquiring an additional 19,316 shares during the period. Invesco Ltd. bought a new position in shares of Galectin Therapeutics in the 4th quarter valued at about $43,000. Royal Bank of Canada grew its position in shares of Galectin Therapeutics by 1,197.3% in the 4th quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock valued at $25,000 after acquiring an additional 5,699 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Galectin Therapeutics in the 1st quarter valued at about $413,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

Read More

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.